Meeting
2015 ASCO Annual Meeting
Phase II study of the PI3K inhibitor BKM120 monotherapy in patients with advanced or recurrent endometrial carcinoma: ENDOPIK, GINECO Study.
Authors
Pierre-Etienne Heudel
Centre Léon Bérard, Lyon, France
Pierre-Etienne Heudel , Michel Fabbro , Celia Roemer-Becuwe , Isabelle Treilleux , Marie-Christine Kaminsky , Antoine Arnaud , Florence Joly , Sophie Roche Forestier , Robert Herve , Isabelle Ray-Coquard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT01397877
Citation
J Clin Oncol 33, 2015 (suppl; abstr 5588)
DOI
10.1200/jco.2015.33.15_suppl.5588
Abstract #
5588
Poster Bd #
146
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303).
First Author: Ken Kato
Poster
2013 ASCO Annual Meeting
Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM).
First Author: Patrick Y. Wen
Poster
2013 ASCO Annual Meeting
PIKHER2: A phase Ib/II study evaluating safety and efficacy of oral BKM120 in combination with lapatinib in HER2-positive, PI3K-activated, trastuzumab-resistant advanced breast cancer.
First Author: Anthony Goncalves
Poster
2011 ASCO Annual Meeting
Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.
First Author: B. Grana